ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock

In recent transactions disclosed by ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a pharmaceutical company with a market capitalization of $1.21 billion and a GREAT financial health score according to InvestingPro, Director Laura Shawver executed a series of stock transactions. On April 7, Shawver sold 50,002 shares of common stock at an average price of $12.301, totaling approximately $615,074. This sale was conducted under a pre-established Rule 10b5-1 trading plan adopted in August 2024. The transaction occurred as SPRY's stock has shown strong momentum, with a 21.61% gain year-to-date.

Additionally, Shawver acquired a total of 50,002 shares through stock options at a price of $4.85 per share. These transactions reflect her continued involvement and investment in ARS Pharmaceuticals, which is known for its focus on pharmaceutical preparations.

Following these transactions, Shawver's direct ownership stands at 210,346 shares. The sales and acquisitions were part of routine financial management and were executed under the guidance of the company's trading plan.

In other recent news, ARS Pharmaceuticals Inc. reported its fourth-quarter 2024 earnings, exceeding analyst expectations with an EPS of $0.51 compared to a forecasted loss of $0.13. The company achieved a total revenue of $86.6 million, significantly surpassing the anticipated $5.1 million. Following these results, Raymond (NSE:RYMD) James analyst Ryan Deschner increased the firm's price target for ARS Pharmaceuticals from $28 to $32, maintaining a Strong Buy rating. This adjustment reflects optimism about the company's earnings and its commercialization strategies for its product, neffy.

The company announced an accelerated timeline for achieving over 80% commercial access to its products, now expected by July 1, 2025, rather than the end of the third quarter. This change aligns with the peak season for epinephrine sales. ARS Pharmaceuticals' management also highlighted a recent agreement with United Health Care, which will provide unrestricted access to neffy starting April 1. This move ensures that a significant portion of commercial patients will have access without prior authorization.

The company's financial model now anticipates higher U.S. net sales projections, with peak worldwide sales expected to reach $1.4 billion. The model includes forecasts for prescription numbers and increased sales, general, and administrative expenses to support commercialization efforts. Additionally, ARS Pharmaceuticals has budgeted $40-$50 million for a direct-to-consumer campaign and is preparing for the global launch of the 1mg neffy dose in May 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.